{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:14:31Z","timestamp":1785352471311,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00347-024-01996-9","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T15:02:33Z","timestamp":1708095753000},"page":"180-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neue und zuk\u00fcnftige Therapieans\u00e4tze in der Behandlung der allergischen Konjunktivitis","New and future treatment approaches for allergic conjunctivitis"],"prefix":"10.1007","volume":"121","author":[{"given":"Stefan","family":"Kassumeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1996_CR1","first-page":"35","volume":"9","author":"L Bielory","year":"2007","unstructured":"Bielory\u00a0L, Katelaris\u00a0CH, Lightman\u00a0S, Naclerio\u00a0RM (2007) Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 9:35","journal-title":"MedGenMed"},{"key":"1996_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","volume":"124","author":"L Bielory","year":"2020","unstructured":"Bielory\u00a0L, Delgado\u00a0L, Katelaris\u00a0CH, Leonardi\u00a0A, Rosario\u00a0N, Vichyanoud\u00a0P (2020) ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol 124:118\u2013134","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1996_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2500\/aap.2013.34.3695","volume":"34","author":"L Bielory","year":"2013","unstructured":"Bielory\u00a0L, Meltzer\u00a0EO, Nichols\u00a0KK, Melton\u00a0R, Thomas\u00a0RK, Bartlett\u00a0JD (2013) An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc 34:408\u2013420","journal-title":"Allergy Asthma Proc"},{"key":"1996_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","volume":"2","author":"A Leonardi","year":"2013","unstructured":"Leonardi\u00a0A (2013) Management of vernal keratoconjunctivitis. Ophthalmol Ther 2:73\u201388","journal-title":"Ophthalmol Ther"},{"key":"1996_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","volume":"108","author":"AC Guidera","year":"2001","unstructured":"Guidera\u00a0AC, Luchs\u00a0JI, Udell\u00a0IJ (2001) Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 108:936\u2013944","journal-title":"Ophthalmology"},{"key":"1996_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5935\/0004-2749.20170045","volume":"80","author":"AXD Costa","year":"2017","unstructured":"Costa\u00a0AXD, Gomes\u00a0JAP, Marculino\u00a0LGC, Liendo\u00a0VL, Barreiro\u00a0TP, Santos\u00a0MSD (2017) Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children. Arq Bras Oftalmol 80:186\u2013188","journal-title":"Arq Bras Oftalmol"},{"key":"1996_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1398-9995.1997.tb00181.x","volume":"52","author":"Q Meng","year":"1997","unstructured":"Meng\u00a0Q, Ying\u00a0S, Corrigan\u00a0CJ et\u00a0al (1997) Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin\u00a05-induced eosinophil degranulation and prolonged survival. Allergy 52:1095\u20131101","journal-title":"Allergy"},{"key":"1996_CR8","first-page":"2686","volume":"37","author":"SM Whitcup","year":"1996","unstructured":"Whitcup\u00a0SM, Chan\u00a0CC, Luyo\u00a0DA, Bo\u00a0P, Li\u00a0Q (1996) Topical cyclosporine inhibits mast cell-mediated conjunctivitis. Invest Ophthalmol Vis Sci 37:2686\u20132693","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1996_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4103\/0301-4738.179727","volume":"64","author":"NS Gokhale","year":"2016","unstructured":"Gokhale\u00a0NS (2016) Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a\u00a0treatment algorithm. Indian J Ophthalmol 64:145\u2013148","journal-title":"Indian J Ophthalmol"},{"key":"1996_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2011.07.004","volume":"128","author":"A Lambiase","year":"2011","unstructured":"Lambiase\u00a0A, Leonardi\u00a0A, Sacchetti\u00a0M, Deligianni\u00a0V, Sposato\u00a0S, Bonini\u00a0S (2011) Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a\u00a0randomized, double-masked, controlled 2\u2011year study. J\u00a0Allergy Clin Immunol 128:896\u2013897","journal-title":"J Allergy Clin Immunol"},{"key":"1996_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2019.11.020","volume":"212","author":"D Bremond-Gignac","year":"2020","unstructured":"Bremond-Gignac\u00a0D, Doan\u00a0S, Amrane\u00a0M et\u00a0al (2020) Twelve-month results of cyclosporine a cationic emulsion in a\u00a0randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol 212:116\u2013126","journal-title":"Am J Ophthalmol"},{"key":"1996_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","volume":"126","author":"A Leonardi","year":"2019","unstructured":"Leonardi\u00a0A, Doan\u00a0S, Amrane\u00a0M et\u00a0al (2019) A\u00a0randomized, controlled trial of cyclosporine a cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology 126:671\u2013681","journal-title":"Ophthalmology"},{"key":"1996_CR13","first-page":"3","volume":"1","author":"E Salami","year":"2022","unstructured":"Salami\u00a0E, Righetti\u00a0G, Cavarzeran\u00a0F, Leonardi\u00a0A (2022) Efficacy and satisfaction of cyclosporine 0.1\u202f% in patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm 1:3","journal-title":"Ocul Immunol Inflamm"},{"key":"1996_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/0301-4738.95878","volume":"60","author":"NS Gokhale","year":"2012","unstructured":"Gokhale\u00a0NS, Samant\u00a0R, Sharma\u00a0V (2012) Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis. Indian J Ophthalmol 60:220\u2013223","journal-title":"Indian J Ophthalmol"},{"key":"1996_CR15","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.jfo.2018.04.009","volume":"42","author":"L Borrego-Sanz","year":"2019","unstructured":"Borrego-Sanz\u00a0L, Lopez Abad\u00a0C, Mendez Fernandez\u00a0R et\u00a0al (2019) Oral cyclosporine for severe vernal keratoconjunctivitis in children. J\u00a0Fr Ophtalmol 42:e12\u2013e13","journal-title":"J Fr Ophtalmol"},{"issue":"e381","key":"1996_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.anai.2019.01.004","volume":"122","author":"H Yazu","year":"2019","unstructured":"Yazu\u00a0H, Shimizu\u00a0E, Aketa\u00a0N et\u00a0al (2019) The efficacy of 0.1\u202f% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Ann Allergy Asthma Immunol 122(e381):387\u2013392","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1996_CR17","first-page":"177","volume":"30","author":"P Labcharoenwongs","year":"2012","unstructured":"Labcharoenwongs\u00a0P, Jirapongsananuruk\u00a0O, Visitsunthorn\u00a0N, Kosrirukvongs\u00a0P, Saengin\u00a0P, Vichyanond\u00a0P (2012) A\u00a0double-masked comparison of 0.1\u202f% tacrolimus ointment and 2\u202f% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 30:177\u2013184","journal-title":"Asian Pac J Allergy Immunol"},{"key":"1996_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/01.ico.0000240091.11854.14","volume":"25","author":"T Stumpf","year":"2006","unstructured":"Stumpf\u00a0T, Luqmani\u00a0N, Sumich\u00a0P, Cook\u00a0S, Tole\u00a0D (2006) Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea 25:1147\u20131149","journal-title":"Cornea"},{"key":"1996_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2018.02.004","volume":"190","author":"S Shin","year":"2018","unstructured":"Shin\u00a0S, Lee\u00a0JH, Lee\u00a0HJ, Chang\u00a0SY, Chung\u00a0SH (2018) Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. Clin Immunol 190:1\u201310","journal-title":"Clin Immunol"},{"key":"1996_CR20","doi-asserted-by":"crossref","unstructured":"Chigbu DI, Labib BA (2021) Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives. Pharm 14:","DOI":"10.3390\/ph14070658"},{"key":"1996_CR21","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt\u00a0A, de Bruin-Weller\u00a0M, Gooderham\u00a0M et\u00a0al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a\u00a01-year, randomised, double-blinded, placebo-controlled, phase\u00a03\u00a0trial. Lancet 389:2287\u20132303","journal-title":"Lancet"},{"key":"1996_CR22","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson\u00a0EL, Bieber\u00a0T, Guttman-Yassky\u00a0E et\u00a0al (2016) Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N\u00a0Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"key":"1996_CR23","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1167\/iovs.05-1261","volume":"47","author":"K Fukuda","year":"2006","unstructured":"Fukuda\u00a0K, Fujitsu\u00a0Y, Kumagai\u00a0N, Nishida\u00a0T (2006) Inhibition of matrix metalloproteinase\u20113 synthesis in human conjunctival fibroblasts by interleukin\u20114 or interleukin-13. Invest Ophthalmol Vis Sci 47:2857\u20132864","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1996_CR24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","volume":"8","author":"K Fukuda","year":"2020","unstructured":"Fukuda\u00a0K, Ebihara\u00a0N, Kishimoto\u00a0T, Fukushima\u00a0A (2020) Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis. J\u00a0Allergy Clin Immunol Pract 8:1152\u20131155","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1996_CR25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/ceo.14142","volume":"50","author":"MC Tsui","year":"2022","unstructured":"Tsui\u00a0MC, Chiang\u00a0BL, Wang\u00a0IJ (2022) Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab. J\u00a0Clin Exp Ophthalmol 50:1100\u20131103","journal-title":"J Clin Exp Ophthalmol"},{"key":"1996_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","volume":"19","author":"CA Utine","year":"2021","unstructured":"Utine\u00a0CA, Li\u00a0G, Asbell\u00a0P, Pflugfelder\u00a0S, Akpek\u00a0E (2021) Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf 19:151\u2013156","journal-title":"Ocul Surf"},{"key":"1996_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","volume":"6","author":"S Doan","year":"2017","unstructured":"Doan\u00a0S, Amat\u00a0F, Gabison\u00a0E, Saf\u00a0S, Cochereau\u00a0I, Just\u00a0J (2017) Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature. Ophthalmol Ther 6:195\u2013206","journal-title":"Ophthalmol Ther"},{"key":"1996_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000508031","volume":"11","author":"A Gatta","year":"2020","unstructured":"Gatta\u00a0A, Della Valle\u00a0L, Farinelli\u00a0A et\u00a0al (2020) Vernal keratoconjunctivitis: a\u00a0case of anti-IgE treatment with short-lasting remission. Case Rep Ophthalmol 11:268\u2013275","journal-title":"Case Rep Ophthalmol"},{"key":"1996_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/ced.15000","volume":"47","author":"C Zengarini","year":"2022","unstructured":"Zengarini\u00a0C, Roda\u00a0M, Schiavi\u00a0C et\u00a0al (2022) Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab. Clin Exp Dermatol 47:604\u2013606","journal-title":"Clin Exp Dermatol"},{"key":"1996_CR30","doi-asserted-by":"crossref","unstructured":"Labib BA, Chigbu DI (2022) Therapeutic targets in allergic conjunctivitis. Pharmaceuticals 15:","DOI":"10.3390\/ph15050547"},{"key":"1996_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/jop.2020.0087","volume":"37","author":"D Clark","year":"2021","unstructured":"Clark\u00a0D, Sheppard\u00a0J, Brady\u00a0TC (2021) A\u00a0randomized double-masked phase\u00a02a trial to evaluate activity and safety of topical ocular reproxalap, a\u00a0novel RASP inhibitor, in dry eye disease. J\u00a0Ocul Pharmacol Ther 37:193\u2013199","journal-title":"J Ocul Pharmacol Ther"},{"key":"1996_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ajo.2021.04.023","volume":"230","author":"D Clark","year":"2021","unstructured":"Clark\u00a0D, Cavanagh\u00a0B, Shields\u00a0AL, Karpecki\u00a0P, Sheppard\u00a0J, Brady\u00a0TC (2021) Clinically relevant activity of the novel RASP inhibitor reproxalap in allergic conjunctivitis: the phase\u00a03 ALLEVIATE trial. Am J Ophthalmol 230:60\u201367","journal-title":"Am J Ophthalmol"},{"key":"1996_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/OPTH.S345324","volume":"16","author":"D Clark","year":"2022","unstructured":"Clark\u00a0D, Karpecki\u00a0P, Salapatek\u00a0AM, Sheppard\u00a0JD, Brady\u00a0TC (2022) Reproxalap improves signs and symptoms of allergic conjunctivitis in an allergen chamber: a\u00a0real-world model of allergen exposure. Clin Ophthalmol 16:15\u201323","journal-title":"Clin Ophthalmol"},{"key":"1996_CR34","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.2147\/OPTH.S441009","volume":"17","author":"CE Starr","year":"2023","unstructured":"Starr\u00a0CE, Nichols\u00a0KK, Lang\u00a0JR, Brady\u00a0TC (2023) The Phase\u00a03 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis. Clin Ophthalmol 17:3867\u20133875","journal-title":"Clin Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-01996-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:03:55Z","timestamp":1709665435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-01996-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-01996-9","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"18 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Kassumeh: Santen GmbH; GSK Deutschland. S.G.\u00a0Priglinger: Alcon\/Novartis, Pharm-Allergan GmbH, Carl Zeiss, BVI, Bayer AG, Bausch & Lomb, \u00d6rtli AG. E.M.\u00a0Messmer: Speaker: Alcon\/Novartis, Bausch & Lomb, Domp\u00e9, Novartis, Santen GmbH, Th\u00e9a Pharma GmbH, TRB-Chemedica AG, VISUfarma; Consultant: Alcon\/Novartis, Alfa Intes, DMG, Domp\u00e9, Kala, Novartis, Santen GmbH, Shire, Sun, Sifi, Th\u00e9a Pharma GmbH, TRB-Chemedica AG, VISUfarma. B.S.\u00a0Brunner gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}